帶狀皰疹疫苗市場規模、佔有率、成長分析、按產品、疫苗類型、按地區 - 產業預測，2024-2031 年

2022年帶狀皰疹疫苗的全球市場規模為39.9億美元，從2023年的42.9億美元成長到2031年的77.1億美元，預計在預測期內（2024-2031年）將以複合年成長率成長。 7.6%。

帶狀皰疹疫苗市場的顯著成長主要是由於60歲及以上老年人患帶狀皰疹的風險增加以及已開發國家醫療保健政策的演變。根據 CDC 報告，大約三分之一的美國一生中會患帶狀皰疹，在美國、加拿大、英國和德國等國家強烈建議接種疫苗，特別是對於COVID-19 感染，這種趨勢變得更加強烈。儘管成本較高，但向創新重組疫苗的轉變正在推動市場前景。 2018 年 CDC 將定序優先於 Zostavax 凸顯了這一趨勢。隨著人口老化，帶狀皰疹患者數量預計將增加，帶狀皰疹疫苗接種作為預防措施的重要性越來越受到人們的認知，從而推動了進一步的採用和市場成長。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 監管環境
• 案例研究

帶狀皰疹疫苗市場規模：依產品分類

• 市場概況
• 定序
• 佐斯塔瓦克斯
• 天空之星

帶狀皰疹疫苗市場規模：依疫苗類型分類

• 市場概況
• 重組疫苗
• 減毒活疫苗

帶狀皰疹疫苗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• GlaxoSmithKline（GSK）
• Merck & Co., Inc.
• Pfizer Inc.
• BioNTech SE
• SK bioscience
• GeneOne Life Science
• Curevo Inc.
• Vaccitech
• Jiangsu Recbio Technology Co., Ltd.
• Changchun BCHT Biotechnology Co.

結論和建議

Global Shingles Vaccine Market size was valued at USD 3.99 billion in 2022 and is poised to grow from USD 4.29 billion in 2023 to USD 7.71 billion by 2031, growing at a CAGR of 7.6% during the forecast period (2024-2031).

The shingles vaccine market is experiencing significant growth, primarily driven by the increased shingles risk among individuals aged 60 and older and advancements in healthcare policies across developed countries. The CDC reports that around one in three Americans will develop shingles in their lifetime, prompting strong vaccination endorsements in countries like the U.S., Canada, the U.K., and Germany, particularly heightened during the COVID-19 pandemic. The shift towards innovative recombinant vaccines, despite their higher costs, is fueling market prospects. The CDC's 2018 preference for Shingrix over Zostavax highlights this trend. With herpes zoster cases expected to rise with aging populations, the importance of shingles vaccination as a preventive measure is becoming increasingly recognized, driving further adoption and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Shingles Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Shingles Vaccine Market Segmental Analysis

Global Shingles Vaccine Market is segmented by product, vaccine type and region. Based on product, the market is segmented into shingrix, zostavax and skyzoster. Based on vaccine type, the market is segmented into recombinant vaccine and live attenuated vaccine. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Shingles Vaccine Market

One of the primary drivers of the global shingles vaccine market is the escalating prevalence of shingles worldwide. This trend is largely attributed to the expanding aging population, which faces a heightened risk of developing shingles and experiencing associated complications. As more individuals reach an age where they are vulnerable to this viral infection, the demand for effective preventive measures grows significantly. Consequently, healthcare providers and patients alike are increasingly recognizing the importance of vaccination, thereby fueling market expansion and emphasizing the need for innovative solutions to mitigate this health concern on a global scale.

Restraints in the Global Shingles Vaccine Market

The Global Shingles Vaccine market faces significant restraints, primarily due to limited vaccine uptake in certain areas. While health authorities strongly advocate vaccination, actual participation is hindered by various factors. These include a lack of awareness about the vaccine's benefits, vaccine hesitancy among potential recipients, and apprehensions regarding possible side effects. These barriers collectively impede the market's expansion and prevent it from reaching its full potential, underscoring the necessity for enhanced educational efforts and outreach programs to address these concerns and improve vaccination rates in the affected regions.

Market Trends of the Global Shingles Vaccine Market

The Global Shingles Vaccine market is experiencing a notable upward trend, primarily fueled by the rising incidence of shingles, particularly among the aging population. As the demographic landscape shifts towards an older average age, the prevalence of herpes zoster infections is surging, prompting an urgent need for effective vaccination solutions. This growing awareness of shingles' potential complications and the effectiveness of available vaccines are further propelling market demand. Additionally, public health initiatives and recommendations from healthcare authorities aimed at increasing vaccination rates are expected to amplify growth, solidifying the shingles vaccine market's pivotal role in preventive healthcare strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Shingles Vaccine Market Size by Product & CAGR (2024-2031)

• Market Overview
• Shingrix
• Zostavax
• Skyzoster

Global Shingles Vaccine Market Size by Vaccine Type & CAGR (2024-2031)

• Market Overview
• Recombinant Vaccine
• Live Attenuated Vaccine

Global Shingles Vaccine Market Size & CAGR (2024-2031)

• North America (Product, Vaccine Type)
  • USA
  • Canada
• Europe (Product, Vaccine Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Vaccine Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Vaccine Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Vaccine Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaccitech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Changchun BCHT Biotechnology Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations